Stocks News

LAST PRICE
44.2700
TODAY'S CHANGE (%)
Trending Down-0.5600 (-1.2492%)

Bid / Lots
44.2300/ 8
Ask / Lots
44.3300/ 1
Open / Previous Close
44.5400 / 44.8300
Day Range
Low 43.2500
High 44.9400
52 Week Range
Low 20.4000
High 53.2850
Volume
126,161
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: AGIO
  
  whether as a result of new information, future events or otherwise, except as required by law.
  
  Contacts:
  
  Investor Contact
  
  Chris Taylor, VP, Investor Relations and Corporate Communications
Nov 1, 2024
- DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones
  12:43PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: AGIO
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 01, 2024 12:43 ET (16:43 GMT)
- DJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones
  10:30AM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: AGIO
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 01, 2024 10:30 ET (14:30 GMT)
Oct 31, 2024
- Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss, from 10:34AM ET on Thursday Oct 31, 2024 by MT Newswires
  10:34AM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: AGIO
  10:34 AM EDT, 10/31/2024 (MT Newswires) -- Agios Pharmaceuticals (AGIO) shares fell 2.7% in recent Thursday trading after the company's Q3 revenue fell below market expectations. The biopharmaceutical company reported Q3 net income Thursday of $16.2...
- -- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q3 Revenue $9.0M, from 6:30AM ET on Thursday Oct 31, 2024 by MT Newswires
  6:30AM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: AGIO
  06:30 AM EDT, 10/31/2024 (MT Newswires) -- ...

Today
- Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO(TM) (imetelstat) in Myeloid Hematologic Malignancies, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: GERN
- Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target, from 4 hours ago by MT Newswires
  4 hours ago by MT Newswires
  Companies Mentioned: IDYA
- DJ Geron Initiated at Buy by HC Wainwright & Co., from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: GERN
- DJ IDEAYA Biosciences Cut to Market Perform From Outperform by Leerink Partners, from 5 hours ago by Dow Jones
  5 hours ago by Dow Jones
  Companies Mentioned: IDYA
Yesterday
- /C O R R E C T I O N -- IDEAYA Biosciences, Inc./, from 8:31AM ET on Monday Nov 04, 2024 by PR Newswire
  8:31AM ET on Monday Nov 04, 2024 by PR Newswire
  Companies Mentioned: IDYA
- CORRECTION -- IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones
  8:30AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: IDYA
- Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin, from 8:00AM ET on Monday Nov 04, 2024 by Dow Jones
  8:00AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: SRRK
- IDEAYA Biosciences Q3 Loss Narrows, from 6:28AM ET on Monday Nov 04, 2024 by MT Newswires
  6:28AM ET on Monday Nov 04, 2024 by MT Newswires
  Companies Mentioned: IDYA
- *DJ IDEAYA Biosciences 3Q Loss/Shr 60c >IDYA, from 6:02AM ET on Monday Nov 04, 2024 by Dow Jones
  6:02AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: IDYA
- IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update, from 6:00AM ET on Monday Nov 04, 2024 by PR Newswire
  6:00AM ET on Monday Nov 04, 2024 by PR Newswire
  Companies Mentioned: IDYA

Agios Pharmaceuticals Inc
NASDAQ:AGIOUnited States

Search Criteria

Today

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 4 hours ago by Dow Jones

Nov 1, 2024

DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones

DJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones

Oct 31, 2024

Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss, from 10:34AM ET on Thursday Oct 31, 2024 by MT Newswires

-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q3 Revenue $9.0M, from 6:30AM ET on Thursday Oct 31, 2024 by MT Newswires

Peers Headlines

Today

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO(TM) (imetelstat) in Myeloid Hematologic Malignancies, from 4 hours ago by Dow Jones

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target, from 4 hours ago by MT Newswires

DJ Geron Initiated at Buy by HC Wainwright & Co., from 4 hours ago by Dow Jones

DJ IDEAYA Biosciences Cut to Market Perform From Outperform by Leerink Partners, from 5 hours ago by Dow Jones

Yesterday

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./, from 8:31AM ET on Monday Nov 04, 2024 by PR Newswire

CORRECTION -- IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin, from 8:00AM ET on Monday Nov 04, 2024 by Dow Jones

IDEAYA Biosciences Q3 Loss Narrows, from 6:28AM ET on Monday Nov 04, 2024 by MT Newswires

*DJ IDEAYA Biosciences 3Q Loss/Shr 60c >IDYA, from 6:02AM ET on Monday Nov 04, 2024 by Dow Jones

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update, from 6:00AM ET on Monday Nov 04, 2024 by PR Newswire